CA2661814A1 - Recombinant hcv e2 glycoprotein - Google Patents

Recombinant hcv e2 glycoprotein Download PDF

Info

Publication number
CA2661814A1
CA2661814A1 CA002661814A CA2661814A CA2661814A1 CA 2661814 A1 CA2661814 A1 CA 2661814A1 CA 002661814 A CA002661814 A CA 002661814A CA 2661814 A CA2661814 A CA 2661814A CA 2661814 A1 CA2661814 A1 CA 2661814A1
Authority
CA
Canada
Prior art keywords
hcv
glycoprotein
modified
variable region
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661814A
Other languages
English (en)
French (fr)
Inventor
Kathleen Mccaffrey
Heidi Drummer
Pantelis Poumbourios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904635A external-priority patent/AU2006904635A0/en
Application filed by Individual filed Critical Individual
Publication of CA2661814A1 publication Critical patent/CA2661814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C07K16/118—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
CA002661814A 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein Abandoned CA2661814A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2006904635A AU2006904635A0 (en) 2006-08-25 Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus
AU2006904635 2006-08-25
AU2006906090A AU2006906090A0 (en) 2006-11-01 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
AU2006906090 2006-11-01
AU2006906282 2006-11-10
AU2006906282A AU2006906282A0 (en) 2006-11-10 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
PCT/AU2007/001221 WO2008022401A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein

Publications (1)

Publication Number Publication Date
CA2661814A1 true CA2661814A1 (en) 2008-02-28

Family

ID=39106399

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002661814A Abandoned CA2661814A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein

Country Status (8)

Country Link
US (2) US8535686B2 (enExample)
EP (1) EP2061805B1 (enExample)
JP (2) JP5674310B2 (enExample)
KR (1) KR101500017B1 (enExample)
CN (1) CN101563362B (enExample)
AU (1) AU2007288129B2 (enExample)
CA (1) CA2661814A1 (enExample)
WO (1) WO2008022401A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
CA2722423A1 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
CN102199613A (zh) * 2010-03-25 2011-09-28 国立大学法人东京大学 感染性丙型肝炎病毒高生产hcv突变体及其应用
AU2011286168B2 (en) 2010-08-04 2015-05-28 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Modified hepatitis C virus proteins
KR20140036127A (ko) * 2010-11-26 2014-03-25 더 맥파레인 버넷 인스티튜트 포 메디칼 리서치 앤드 퍼블릭 헬스 리미티드 조성물 및 방법
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus
CN103102394B (zh) * 2013-02-27 2014-06-25 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi49及其应用
EP3519424A4 (en) * 2016-09-29 2020-06-03 Macfarlane Burnet Institute for Medical Research and Public Health Limited ASSEMBLED GLYCOPROTEINS
US11008368B2 (en) * 2019-07-26 2021-05-18 The Scripps Research Institute Engineered HCV E2 immunogens and related vaccine compositions
US20230181726A1 (en) * 2020-05-11 2023-06-15 Macfarlane Burnet Institute For Medical Research And Public Health Limited A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2201703A1 (en) * 1994-10-21 1996-05-09 Geert Maertens New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
AU1462300A (en) 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
AU7602800A (en) 1999-09-23 2001-04-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2002022155A1 (en) 2000-09-13 2002-03-21 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
AR035867A1 (es) * 2001-04-24 2004-07-21 Innogenetics Nv Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e
IL145440A0 (en) * 2001-09-13 2002-06-30 Xtl Biopharmaceuticals Ltd Synthetic hcv envelope proteins and their use for vaccination
JP5138230B2 (ja) * 2004-01-07 2013-02-06 サード・ウェーブ・テクノロジーズ・インク Ｃ型肝炎ウイルスの遺伝子型の決定方法
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein

Also Published As

Publication number Publication date
US8535686B2 (en) 2013-09-17
US9598467B2 (en) 2017-03-21
EP2061805A1 (en) 2009-05-27
JP2010501594A (ja) 2010-01-21
EP2061805A4 (en) 2010-08-04
KR101500017B1 (ko) 2015-03-09
US20140120127A1 (en) 2014-05-01
JP5674310B2 (ja) 2015-02-25
AU2007288129A1 (en) 2008-02-28
AU2007288129B2 (en) 2013-03-07
CN101563362B (zh) 2015-02-11
CN101563362A (zh) 2009-10-21
KR20090053930A (ko) 2009-05-28
WO2008022401A1 (en) 2008-02-28
JP2014240427A (ja) 2014-12-25
JP5999524B2 (ja) 2016-09-28
US20110014209A1 (en) 2011-01-20
EP2061805B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
AU2007288129B2 (en) Recombinant HCV E2 glycoprotein
JP2010501594A6 (ja) 組換えｈｃｖ ｅ２糖タンパク質
Vietheer et al. The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs
Meunier et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus
KR102558839B1 (ko) 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
Heile et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates
EP3094644B1 (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
JP6942309B2 (ja) フラビウイルスウイルス様粒子
RS56737B1 (sr) Humana monoklonska antitela koja su specifična za protein e virusa denge serotipa 1 i njihove upotrebe
CA2125700A1 (en) Hepatitis e virus peptide antigens and antibodies
Krapchev et al. Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice
EP2481424A1 (en) Improvements in or relating to treatment and prevention of hepatitis C viral infections
US9884109B2 (en) Compositions and methods
Kachko et al. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles
Torresi et al. A self‐adjuvanting multiepitope immunogen that induces a broadly cross‐reactive antibody to hepatitis C virus
El-Awady et al. Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro
US20030091590A1 (en) Recombinant rhabdoviruses as live-viral vaccines
WO2002089728A2 (en) Recombinant rhabdoviruses as live-viral vaccines
Vasiliauskaite Structural characterization of viral envelope glycoproteins
Wong Characterization of the Humoral Immune Response Elicited Against a Prophylactic Vaccine Composed of Recombinant Envelope Glycoproteins from Hepatitis C Virus
Naik In vitro infectivity of the Hepatitis C Virus in the context of humoral immunity and immune escape
Migliaccio core| E||| E2| p7|
WO2014065822A1 (en) Hepatitis c virus neutralizing epitopes, antibodies, and methods
HK1173979A (en) Improvements in or relating to treatment and prevention of hepatitis c viral infections

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20181205